GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Merrimack Pharmaceuticals Inc (NAS:MACK) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)

Merrimack Pharmaceuticals (Merrimack Pharmaceuticals) Total Revenue Growth Rate (Future 3Y To 5Y Est) : N/A (As of Apr. 27, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Merrimack Pharmaceuticals Total Revenue Growth Rate (Future 3Y To 5Y Est)?

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, Merrimack Pharmaceuticals's Total Revenue Growth Rate (Future 3Y To 5Y Est) is N/A.

Competitive Comparison of Merrimack Pharmaceuticals's Total Revenue Growth Rate (Future 3Y To 5Y Est)

For the Biotechnology subindustry, Merrimack Pharmaceuticals's Total Revenue Growth Rate (Future 3Y To 5Y Est), along with its competitors' market caps and Total Revenue Growth Rate (Future 3Y To 5Y Est) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Merrimack Pharmaceuticals's Total Revenue Growth Rate (Future 3Y To 5Y Est) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Merrimack Pharmaceuticals's Total Revenue Growth Rate (Future 3Y To 5Y Est) distribution charts can be found below:

* The bar in red indicates where Merrimack Pharmaceuticals's Total Revenue Growth Rate (Future 3Y To 5Y Est) falls into.


Merrimack Pharmaceuticals  (NAS:MACK) Total Revenue Growth Rate (Future 3Y To 5Y Est) Explanation

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.

Merrimack Pharmaceuticals Total Revenue Growth Rate (Future 3Y To 5Y Est) Related Terms

Thank you for viewing the detailed overview of Merrimack Pharmaceuticals's Total Revenue Growth Rate (Future 3Y To 5Y Est) provided by GuruFocus.com. Please click on the following links to see related term pages.

Merrimack Pharmaceuticals (Merrimack Pharmaceuticals) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Merrimack Pharmaceuticals Inc (NAS:MACK) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)
Comparable Companies
PSTX CRMD CBUS IMRX DNTH GRTS IVVD ATXS INZY FATE OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
One Broadway, 14th Floor, Cambridge, MA, USA, 02142
Website
https://www.merrimack.com
Merrimack Pharmaceuticals Inc is a biotechnology company that discovers, develops, and commercializes innovative medicines that consist of novel therapeutics paired with diagnostics to treat cancer. The company's core approach to systems biology is to apply multidisciplinary capabilities to build functional and predictive computational models of biological systems, such as cell signaling networks. Merrimack also enters into third-party agreements to further process and commercialize its products.
Executives
Eric Andersen director, other: See Remarks 1507 BERKELEY ST, SUITE 7, SANTA MONICA X1 90404
Gary L Crocker director, officer: President MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Noah G. Levy director, other: See Remarks 60 EAST 42ND ST, 9TH FLOOR, NEW YORK NY 10165
Ana Radeljevic director 2430 BEACON STREET, UNIT 201, CHESTNUT HILL MA 02467
Ulrik B. Nielsen director MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Russell T Ray director 2525 DUPONT DR, IRVINE CA 92612
Newtyn Capital Partners, Lp other: See Remarks 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Ledo Capital, Llc other: See Remarks 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Newtyn Te Partners, Lp other: See Remarks 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Newtyn Partners, Lp other: See Remarks 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Western Standard Partners Qp, L.p. other: See Remarks 5900 WILSHIRE BLVD, SUITE 650, LOS ANGELES CA 90036
Western Standard Partners Lp other: See Remarks 5900 WILSHIRE BLVD, SUITE 650, LOS ANGELES CA 90036
Western Standard Llc other: See Remarks 5757 WILSHIRE BLVD, SUITE 636, LOS ANGELES CA 90036
Newtyn Management, Llc other: See Remarks 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
22nw Gp, Inc. 10 percent owner, other: See Explanation of Responses 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107